BPC-157

BPC-157 is a synthetic pentadecapeptide of fifteen residues (GEPPPGKPADDAGLV) described in the literature as a partial sequence derived from a protein fraction isolated from gastric juice. It is supplied as a lyophilised white powder as its acetate salt. Identity for laboratory material is established by mass spectrometry against the calculated monoisotopic mass and by retention time on a reversed-phase HPLC method; sequence confirmation is not implied by purity data alone. The analytical values published on this record — CAS reference, molecular formula, molar mass and purity specification — are transcribed from the supplier specification sheet and the batch certificate of analysis and are not inferred from literature values.

The name refers in the literature to the free peptide sequence, while commercial material is normally the acetate salt, and the two differ in mass and in assay figures reported on a per-weight basis. Peptide content, when reported separately from chromatographic purity, is the value that reflects how much peptide is present in the vial as opposed to counter-ion and residual water. A certificate reporting a purity percentage without stating the method, the gradient and the detection wavelength cannot be compared meaningfully against another supplier's certificate.

The sequence was described in the 1990s by a Croatian research group working on gastric protective fractions, and the large majority of the published record since then originates from that group and its collaborators. This concentration of authorship is itself an evidentiary fact worth stating: it means much of the literature shares methods, animal facilities and analytical assumptions. Independent replication outside that network exists but is limited, and reviews of the field have noted the same concentration. Interest in the sequence has been sustained rather than driven by regulatory development; no marketing authorisation exists in any major jurisdiction.

Published work in rodent models has examined effects on angiogenic signalling, including reports of altered VEGF receptor 2 expression and downstream nitric oxide pathway involvement. Other reports describe interaction with the nitric oxide system under experimental conditions in which NO synthesis is pharmacologically blocked or promoted, and effects on growth-factor signalling in cultured tendon-derived fibroblasts. Additional studies examine gastrointestinal mucosal integrity models and models of experimentally induced vascular occlusion. These are mechanistic observations in defined experimental systems; they describe what was measured in an assay, not an effect established in intact humans.

A second strand of the literature examines effects on neurotransmitter systems in rodent models, including reports of interaction with dopaminergic and serotonergic signalling under experimentally perturbed conditions, and a further strand examines corticosteroid-induced and NSAID-induced gastrointestinal lesion models. Several papers report effects on collagen organisation and tensile measurements in healing rodent tendon, and others report altered expression of growth factor receptors in cultured tendon fibroblasts. It is worth being precise about what such a result is: a change in a measured variable within a constructed model, under conditions chosen by the investigator, in a species whose repair biology differs materially from human tissue.

The consistent finding across the rodent literature is that the peptide is well tolerated at the exposures tested, with published toxicity screening reporting no lethal dose identified in the ranges examined. Effects in experimentally injured rodent tendon, muscle and gastrointestinal tissue have been reported repeatedly across multiple papers and several injury models, which is a meaningful degree of internal consistency. In vitro work on fibroblast migration and outgrowth has been reproduced in more than one laboratory. Stability of the lyophilised solid under recommended storage is well characterised by supplier data.

There are no completed randomised controlled human trials establishing efficacy for any indication. The human record consists of early-phase safety work and case-level reports; it does not support any efficacy claim. Almost all positive findings originate in rodent models, and the rodent studies typically use small group sizes, short observation windows and injury models that are induced surgically or chemically rather than occurring naturally. Blinding and randomisation are inconsistently reported. Because authorship is concentrated in a small number of related groups, apparent replication across papers is weaker evidence than the paper count suggests. Pharmacokinetic characterisation in humans is essentially absent, and oral bioavailability claims that circulate informally are not supported by published human data. A reader evaluating this compound should treat the entire efficacy literature as hypothesis-generating.

Two further gaps deserve naming. First, the material used in published animal work is research-grade peptide characterised to the standard of the laboratory that produced it, and the papers rarely publish identity or purity data at all; a reader cannot assume that what was studied matches what a supplier ships. Second, negative or null results in this field are unlikely to be published, and with a literature dominated by a small number of groups the file-drawer effect is a plausible contributor to the apparent consistency of positive findings. Neither of these is a reason to dismiss the compound as a research subject; both are reasons to reject confident claims about it.

The lyophilised solid is stored per the storage conditions on this record, protected from light and moisture, with the vial equilibrated to ambient temperature before opening to limit condensation. Repeated freeze-thaw of reconstituted material and prolonged ambient exposure are the two handling variables most often implicated in analytical degradation. Handling described here concerns the material as supplied in a laboratory setting; this record contains no preparation, administration or dosing procedure of any kind.

Indexed citations for this compound appear in the literature section below, each linked to its PubMed record by PMID so the primary source can be read directly. Only records verified against PubMed are listed; nothing is cited from secondary summaries. See our testing methodology for the analytical basis of the specification values and sourcing standards for documentation requirements.